53rd week of 2020 patent applcation highlights part 9 |
Patent application number | Title | Published |
20200405633 | TREATING GYNECOLOGICAL MALIGNANCIES WITH DEPLOYABLE IMPLANTS - A method of treating a gynecological malignancy includes introducing an implant within a uterus of a patient and positioning the implant adjacent to an endometrium of the uterus to enable a bioactive agent supported on the implant to treat the gynecological malignancy. The implant may be one or more deployable implants including a balloon, an IUD, a stent, or combinations thereof. Such implants may be introduced by one or more surgical instruments. | 2020-12-31 |
20200405634 | EYE DROPS IN FORM OF SOLUTION COMPRISING BENZOPYRAN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention provides an eye drop formulation in the form of a solution, comprising | 2020-12-31 |
20200405635 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM - An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track. | 2020-12-31 |
20200405636 | OPHTHALMIC PRODUCT WITH ANTIOXIDATIVE FUNCTION - An ophthalmic product having an antioxidative function includes an ophthalmic composition. The ophthalmic composition includes gold nanoparticles and at least one antioxidative auxiliary ingredient. The effective concentration of the gold nanoparticles is from 0.01 ppm to 3000 ppm. The content of the at least one antioxidative auxiliary ingredient is greater than 0 wt % and less than 20 wt % based on 100 wt % of the ophthalmic composition. | 2020-12-31 |
20200405637 | OIL-BASED WOUND CARE COMPOSITIONS AND METHODS - Compositions and methods for wound care or the dressing or treatment of wounds in a subject in need thereof. The compositions include an oil-based carrier, a polar solvent comprising one or more polar antimicrobial agents, and collagen or a collagen-based material. In at least some instances, the polar solvent comprising the one or more polar antimicrobial agents and the collagen or collagen-based material are suspended in the oil-based carrier. | 2020-12-31 |
20200405638 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS - The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents. | 2020-12-31 |
20200405639 | NOVEL DELIVERY OF LARGE PAYLOADS - The disclosure includes non-naturally occurring or engineered CRISPR systems and proteins, associated with a delivery system comprising a virus component and a lipid component. The disclosure includes CRISPR proteins associated with capsid proteins, e.g., AAV VP!, VP2, and/or VP3, on the surface of or internal to the AAV, along with compositions, systems and complexes involving the AAV-CRISPR protein, nucleic acid molecules and vectors encoding the same, deliver}-systems, and uses therefor. | 2020-12-31 |
20200405640 | SYNTHETIC EXTRACELLULAR VESICLES FOR NOVEL THERAPIES - Given developing resistance of tumor cells to current chemotherapeutic and targeted therapeutic agents, novel cancer therapies with enhanced potency and specificity are substantially required. Applicant has provided herein extracellular nanoparticle vesicles that redirect immune effector cells towards cancer cells for killing. Relative to conventional immunotherapeutic antibodies with defined orientation and geometry for their distinct antigen-binding arms, antibodies displayed on spherical exosomes can promote formation of immunological synapses as well as enhanced efficacy to activate immune cells. | 2020-12-31 |
20200405641 | A LIPID-BASED COATING COMPOSITION, AND AN OBJECT HAVING A LIPID-BASED COATING - A lipid-based coating composition for coating a medical device, wherein the coating composition includes a) lipid vesicles consisting of i. 85-95 mol % of a phospholipid (A) having a phosphatidylcholine group; ii. 5-12 mol % of a PEGylated phospholipid (B); optionally 0-3 mol % of a lipophilic compound (C) other than lipids (A) and (B); b) 0-5 wt. % of a water-soluble additive (D); and c) at least 95 wt. % of water, wherein lipid vesicles having a number average size between 50 and 140 nm (measured according to dynamic light scattering) and wherein the lipid vesicle concentration ranges between 0.025 mg/ml and 2 mg/ml, and wherein the mol % of lipids (A), (B) and (C) is calculated relative to the total molar amount of lipids (A)+(B)+(C) in the lipid-based coating composition and wherein the wt. % of water-soluble additive (D) is calculated relative to the weight of the total composition. Preferably the medical device is a contact lens, a catheter or a medical implant. | 2020-12-31 |
20200405642 | TOLEROGENIC LIPOSOMES AND METHODS OF USE THEREOF - The invention provides compositions (e.g., liposomes) for treating diseases and conditions associated with pathologic immune responses and methods for formulating and administering such compositions. | 2020-12-31 |
20200405643 | DRUG COMPOSITIONS CONTAINING POROUS CARRIERS MADE BY THERMAL OR FUSION-BASED PROCESSES - Pharmaceutical compositions for improving the solubility and dissolution of poorly soluble drugs, which contain a therapeutic agent, a pharmaceutically acceptable polymer, and a mesoporous carrier. These pharmaceutical compositions have been prepared by thermal processes and fusion-based high energy mixing processes that do not require external heat input to obtain a composition that shows improved properties. Also provided herein are methods of preparing and use thereof | 2020-12-31 |
20200405644 | CONTROLLED RELEASE FORMULATIONS FOR THE INDUCTION AND PROLIFERATION OF BLOOD CELLS - The absence of regulatory T cells (Treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of Treg through in situ Treg expansion or induction is contemplated herein as a treatment option for these disorders. Current methods for in vivo Treg expansion are not Treg specific and are associated with many adverse side-effects. The data presented herein provides in vitro testing of a Treg-inducing microparticle providing a predictable controlled release for combinations of cytokines and drugs (e.g., IL-2, TGF-β, and/or rapamycin) resulting in targeted Treg migration. These controlled release microparticles are also capable of inducing FoxP3+ Treg in human cells in vitro suggesting that these compositions be developed into an in vivo Treg induction and expansion therapy. | 2020-12-31 |
20200405645 | IBUPROFEN AND ACETAMINOPHEN TABLET - The present invention provides novel compositions, methods of treatment and methods of manufacture of large scale, commercially viable ibuprofen and acetaminophen tablets. The unique characteristics and synergistic effects resulting from the disclosed compositions, methods of treatment and methods of manufacture demonstrate a product with optimal analgesia, anti-pyresis, safety profiles and large-scale manufacturability. The inventions described herein surprisingly show the unique composition and method of manufacturing for a large-scale commercial batch of a novel ibuprofen and acetaminophen tablet. | 2020-12-31 |
20200405646 | PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS THEREOF - The invention provides various novel compositions of berberine in combination with pharmacologically active EPA and DHA, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity. Additionally, the pharmaceutical compositions of the invention are useful in treating and/or preventing atherosclerosis, heart diseases, neurodegenerative diseases, inflammation, cancers, as well as various liver diseases or disorders, such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. Furthermore, the pharmaceutical compositions of the invention are useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases. | 2020-12-31 |
20200405647 | SHELL COMPOSITION AND CAPSULE USING THE SHELL COMPOSITION - Provided is a shell composition that is formed with a water-insoluble powder such as starch and/or a water-soluble polymer such as dextrin as a base component, and with locust bean gum and/or xanthan gum as a gelling agent. This shell composition enables a novel shell composition which can favorably form a shell without using carrageenan, has favorable properties that enable the shell composition to substitute traditional shells that use a gelatin shell or carrageenan, and comprises a plant-derived base. | 2020-12-31 |
20200405648 | APOMORPHINE-PALMITIC ACID COCRYSTAL SOLID PARTICLE CRYSTALLINE FORM - A pharmaceutical composition comprising apomorphine (APO) in a solid crystalline form, wherein the solid crystalline form is an APO·palmitic acid cocrystal solid particle crystalline form. | 2020-12-31 |
20200405649 | DNA ORIGAMI NANOPARTICLE DELIVERY OF PROGRAMMED CHROMOSOME BREAKAGE MACHINERY - Compositions of the present disclosure include a first dCas9-FokI-sgRNA complex and a second dCas9-FokI-sgRNA complex. The first sgRNA is configured to target a first side of a genomic fusion site and the second sgRNA is configured to target a second side of the genomic fusion site. The first and second complexes only cut DNA upon dimerization. Thus, upon binding of both first dCas9-FokI-sgRNA complex and second dCas9-FokI-sgRNA complex, the dimer is produced and DNA cleavage proceeds at the genomic fusion site. The dCas9-FokI-sgRNA complexes are loaded on a folded-DNA shell for transport across the cellular membrane. The shell has a viral-mimic structure that maximizes cell entry, is non-cytotoxic, has low-to-nonimmunogenicity, and provides excellent capacity to enclose and protect the complexes. These systems exhibit both cellular (via the shell) and molecular (via the complexes) specificity, significantly reducing off-target activity and the associated harmful side-effects. | 2020-12-31 |
20200405650 | STARRY MESOPOROUS SILICA NANOPARTICLES AND SUPPORTED LIPID BI-LAYER NANOPARTICLES - The present disclosure is directed to methods of producing star-like mesoporous silica nanoparticles (SMSNPs) and protocells SMSNPs and their use for targeted drug delivery formulations and systems and for biomedical applications. Also provided are methods of producing monosized protocells from monodisperse SMSNPs and their use for targeted drug delivery formulations and systems and for biomedical applications. | 2020-12-31 |
20200405651 | POROUS PARTICLE AND METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION - A porous particle, wherein the porous particle has a mass median aerodynamic diameter and a volume average particle diameter that satisfy expression: y≥2x, where x denotes the mass median aerodynamic diameter and y denotes the volume average particle diameter, and the porous particle has a relative span factor (R.S.F) that satisfies expression: 0<(R.S.F)≤1.5. | 2020-12-31 |
20200405652 | METHYLPHENIDATE-CONTAINING PATCH - The present invention addresses the problem of providing a methylphenidate-containing patch that maintains a suitable adhesion to skin over a long period of time and has a sustained drug efficacy and an excellent handeleability. The present invention relates to a patch comprising a backing layer and an adhesive layer, wherein the adhesive layer contains methylphenidate, a rubber-based adhesive base, and a tackifying resin. The rubber-based adhesive base contains a styrene-isoprene-styrene block copolymer, and the tackifying resin contains a terpene-based resin and an alicyclic saturated hydrocarbon resin. The present invention further relates to a method for producing the patch. | 2020-12-31 |
20200405653 | METHYLPHENIDATE-CONTAINING TRANSDERMAL PATCH - The present invention addresses the problem of providing a methylphenidate-containing transdermal patch in which cold flow beyond the edge of the patch containing methylphenidate is inhibited, and which has sufficient physical properties as a preparation, and excellent handleability. The present invention pertains to: a transdermal patch comprising a backing layer and an adhesive layer, wherein the adhesive layer contains methylphenidate, a rubber-based adhesive agent, and an acrylic adhesive agent, and the mixing ratio of the rubber-based adhesive agent to the acrylic adhesive agent is 9:1 to 1:9, and a production method for the transdermal patch. | 2020-12-31 |
20200405654 | CALCIUM SILICATE-CONTAINING ACRYLIC ADHESIVE PATCH - A problem addressed by the present invention is to provide an adhesive patch, which contains an acrylic adhesive base material, is easy to handle, prevents cold flow independently of physical properties and concentrations while being kept in a packaging material or being adhered, and during storage, keeps the drug in the adhesive patch stable and maintains the suitable administration form of the drug over a long period so that the drug can provide sufficient medicinal effect for a long time. The present invention relates to an adhesive patch provided with a backing layer and an adhesive agent layer, the adhesive agent layer containing a drug, an acrylic adhesive base material, and calcium silicate. The present invention also relates to a method for producing the adhesive patch. | 2020-12-31 |
20200405655 | METHOD FOR ACCELERATING WOUND HEALING - Disclosed is a method and composition for accelerating wound healing comprising applying a dressing directly on a subject's wound immediately or no later than 72 hours following injury. The dressing reduces or minimizes scarring, prevents or reduces infection, inhibits or reduces internal bleeding, inhibits or reduces external discharge, provides protection from sun and/or UV rays or a combination thereof, thereby accelerating wound healing. | 2020-12-31 |
20200405656 | MULTILAYER COMPOSITE MATERIAL - The present invention relates to a multilayer composite material for the treatment of wounds and lesions and to a dressing comprising said multilayer material. | 2020-12-31 |
20200405657 | TREATMENT OF PAIN USING ALLOSTERIC MODULATOR OF TRPV1 - Provided herein are methods of treating pain using pharmaceutical compositions that comprise an allosteric modulator of TRPV1, optionally in admixture with a TRPV1 ligand. The pharmaceutical composition is substantially free of THC and THCA. Also provided are methods of identifying an allosteric modulator of TRPV1 by analyzing binding to a specific binding pocket in TRPV1 and designing a complex mixture comprising the allosteric modulator for treating pain. | 2020-12-31 |
20200405658 | TWO-PART NITRIC OXIDE GENERATING TOPICAL COMPOSITIONS - A two-part topical composition includes a first composition including a S-nitrosothiol nitric oxide donor and a carrier, and a second composition including zinc oxide. The second composition is to be mixed with the first composition. The zinc oxide reacts with the S-nitrosothiol nitric oxide donor at a temperature ranging from about 20° C. to about 40° C. to enhance a rate of release of nitric oxide from a mixture of the first composition and the second composition. | 2020-12-31 |
20200405659 | COMPOSITION CONTAINING 2,3-BUTANEDIOL AS ACTIVE INGREDIENT - A method for treating an inflammatory disease, a skin disease or a skin wrinkle according to an embodiment of the present invention includes administering or applying a composition including 1,2-butandediol to a subject in need thereof. The composition including-butanediol may be used as an anti-inflammatory, anti-oxidative or anti-wrinkle active ingredient. 2,3-butanediol can be used as an active ingredient of a pharmaceutical or cosmetic composition. | 2020-12-31 |
20200405660 | TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATION - Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation. | 2020-12-31 |
20200405661 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING ARTHRITIS - Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins. | 2020-12-31 |
20200405662 | Hexylamine Salts and Methods of Using Hexylamine - Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and/or memory in a human subject. | 2020-12-31 |
20200405663 | R-KETAMINE AND DERIVATIVE THEREOF AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEURODEGENERATION DISEASE OR RECOGNITION FUNCTIONAL DISORDER - The present invention is to provide a preventive or therapeutic agent for a neurodegenerative disease or a cognitive dysfunction, containing a compound represented by a following formula (I) or a pharmacologically acceptable salt thereof as an active ingredient. | 2020-12-31 |
20200405664 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2020-12-31 |
20200405665 | METHODS FOR THE TREATMENT OF ROSACEA - The present invention relates to pharmaceutical compositions for topical use (including also dermatological compositions), for treating skin conditions and afflictions, such as rosacea and symptoms and conditions associated there from. | 2020-12-31 |
20200405666 | TREATMENT OF SYMPTOMS ASSOCIATED WITH FEMALE GASTROPARESIS - Nasal formulations of metoclopramide are administered for the treatment of symptoms associated with female gastroparesis. Also provided are methods of treating symptoms of female gastroparesis with nasal metoclopramide. | 2020-12-31 |
20200405667 | [18F]-LABELLED LACTATE DERIVATIVE AS PET RADIOTRACER - A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [18F]-labelled lactate derivative. Also, a process for the radiosynthesis of the [18F]-labelled lactate derivative. Further, the use of the [18F]-labelled lactate derivative for imaging lactate uptake in living cells, especially in humans. | 2020-12-31 |
20200405668 | Compositions and Methods of Use of beta-hydroxy-beta-methylbutyrate (HMB) for Decreasing Fat Mass - The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance or promote lipolysis, increase adipocyte fat oxidation, induce adipocyte and muscle mitochondrial biogenesis, increase energy expenditure, decrease total body weight and increase body fat loss. | 2020-12-31 |
20200405669 | SOBETIROME IN THE TREATMENT OF MYELINATION DISEASES - Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof. | 2020-12-31 |
20200405670 | METHOD, COMPOSITION AND PACKAGE FOR BOWEL CLEANSING - The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy. | 2020-12-31 |
20200405671 | METHODS AND MATERIALS FOR TREATING POLYCYSTIC KIDNEY DISEASE - This document relates to methods and materials for treating polycystic kidney disease (PKD) and/or a complication associated with a PKD (e.g., a cardiovascular complication). For example, one or more betaines (e.g., trimethylglycine) can be administered to a mammal having, or at risk of developing, a PKD to treat the mammal. | 2020-12-31 |
20200405672 | METHODS FOR TREATING PSYCHIATRIC DISEASES AND DISORDERS AND THE SYMPTOMS THEREOF IN A SUBJECT BY ADMINISTERING AN ANTAGONIST OF THE NA+-K+-2CL- CATION-CHLORIDE COTRANSPORTER ISOFORM 1 (NKCC1) - Disclosed are methods for treating a psychiatric disease or disorder and/or symptoms thereof in a subject in need thereof, the method comprising administering to the subject an effective amount of an antagonist of the Na+-K+-2Cl— cation-chloride cotransporter isoform 1 (NKCC1) for treating the psychiatric disorder and/or the symptoms thereof in the subject. The methods further may include administering to the subject a dopamine D1 agonist and/or a GABA | 2020-12-31 |
20200405673 | ORAL SOLUTION AND POWDER TO LIQUID COMPOSITIONS OF BALSALAZIDE - A pharmaceutical composition for preparation of an orally administered liquid solution containing a therapeutically sufficient dose of dissolved balsalazide. The composition further comprises three artificial sweeteners comprising sucralose, acesulfame potassium and ammonium glycyrrhizinate that unexpectedly mitigate the bitter attributes of the orally administered liquid balsalazide solution that would otherwise render the solution unpalatable. More particularly, the present disclosure relates to a composition of the three artificial sweeteners and a therapeutically sufficient dose of balsalazide for the treatment of bowel disorders such as ulcerative colitis. Unit dose sachets of balsalazide disodium 750 mg and 2,250 mg of powder to oral solution are also disclosed. The disclosure further provides a kit including a dissolvable solid phase composition of the three artificial sweeteners and dissolvable solid phase therapeutically sufficient dose of balsalazide and further comprising a therapeutic dose of a probiotic ( | 2020-12-31 |
20200405674 | METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES - The present invention relates to the use of serine or threonine together with at least one further amino acid or amino acid derivative and with at least one calcium salt or its hydrate to increase cellular availability of calcium in living cells of the epidermis and to a specific mixture of such components and a formulation consisting of said mixture and a solvent. | 2020-12-31 |
20200405675 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2020-12-31 |
20200405676 | MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER - The present invention relates to a compound, in particular a meroterpenoid compound, or salt thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition is also provided. | 2020-12-31 |
20200405677 | Compositions and Methods for Lowering Triglycerides Without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 2020-12-31 |
20200405678 | METHODS OF TREATING UREA CYCLE DISORDERS - The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age. | 2020-12-31 |
20200405679 | EXTENDED DURATION LOCAL ANESTHETIC FORMULATION - An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration. | 2020-12-31 |
20200405680 | TRANSDERMAL FORMULATIONS - The present disclosure is directed to transdermal compositions comprising isothiocyanates or isocyanates. | 2020-12-31 |
20200405681 | METHODS FOR TREATING MELANOMA - The present invention is directed to a method for preventing and/or treating melanoma such as superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method optionally comprising co-administering anti-PD-1 antibody with dapansutrile. A preferred route of administration is oral administration. | 2020-12-31 |
20200405682 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES - Disclosed are methods useful for the topical therapeutic treatment of cervical intraepithelial neoplasia (CIN) and/or cervical cancer using compositions containing nanoparticles of paclitaxel or other taxanes. | 2020-12-31 |
20200405683 | EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME - The present invention relates to efflux inhibitor compositions and methods of using these agents for treating conditions where the activity of efflux transporter proteins (e.g., Breast Cancer Resistance Protein (BCRP) and P-Glycoprotein (P-GP)) inhibit effective delivery of a therapeutic agent to a target tissue (e.g., brain, spinal cord, nerves, cerebrospinal fluid, testis, eyeballs, retina, inner ear, placenta, mammary gland, liver, biliary tract, kidney, intestines, lung, adrenal cortex, endometrium, hematopoietic cells, and/or stem cells). | 2020-12-31 |
20200405684 | Taxane Particles and Their Use - Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm | 2020-12-31 |
20200405685 | HIGH CANNABIGEROL CANNABIS PLANTS, METHODS OF PRODUCING AND METHODS OF USING THEM - The invention provides compositions and methods for the breeding, production, processing and use of Specialty | 2020-12-31 |
20200405686 | DEFINED DOSE CANNABIS PUCK - This invention relates to novel products of compressed | 2020-12-31 |
20200405687 | METHODS FOR THE TREATMENT OF INFECTION - The invention provides methods for treating an infection in a subject in need thereof by administering to the subject a pharmaceutical composition including ajulcmic acid, or a pharmaceutically acceptable salt thereof. In various embodiments, the infection may be a bacterial, viral, or fungal infection. The invention also features methods of treating an infection in a subject in need thereof by administering to the subject ajulemic acid, or a pharmaceutically acceptable salt thereof, and a suitable antibiotic, antifungal, or antiviral. | 2020-12-31 |
20200405688 | METHODS AND MATERIALS FOR TREATING CANCER - This document provides methods and materials for treating cancer. For example, methods and materials for using one or more schweinfurthin compounds and one or more immune-checkpoint inhibitors to treat a mammal having cancer are provided. | 2020-12-31 |
20200405689 | INHIBITION OF DIPEPTIDE REPEAT PROTEINS - Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs). | 2020-12-31 |
20200405690 | THIOUREYLENE LIQUID COMPOSITIONS - The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats. | 2020-12-31 |
20200405691 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS - Disclosed herein are methods of treating a subject with a bacterial infection, or preventing a bacterial infection, comprising administering to the subject an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. Also described are methods of inhibiting bacterial growth in a plant comprising contacting the plant with an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. The methods are effective against an array of bacterial pathogens in various animals and plants. | 2020-12-31 |
20200405692 | USE OF ISOXAZOLINE COMPOUNDS FOR TREATING DEMODICOSIS - The present invention relates to methods of treating demodicosis by administering an isoxazoline compound of formula (I) | 2020-12-31 |
20200405693 | REDUCED DOSE METAXALONE FORMULATIONS - Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability. | 2020-12-31 |
20200405694 | METHODS OF INHIBITING TUMOR METASTASIS - Thromboxane A2 receptor antagonists, such as ifetroban, inhibit solid tumor metastasis. The formation of surface and microscopic lung metastases are inhibited. Thromboxane A2 receptor antagonists can inhibit the tumor metastasis process without affecting the growth or development of a primary tumor. | 2020-12-31 |
20200405695 | CANCER THERAPEUTIC - O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-L-tyrosine or a pharmacologically acceptable salt thereof exhibits high therapeutic effects on bile duct cancer, colorectal cancer, esophageal cancer, breast cancer, and pancreatic cancer. | 2020-12-31 |
20200405696 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE - The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia the treatment of cancer is disclosed. | 2020-12-31 |
20200405697 | Antitumor Agent - The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof. | 2020-12-31 |
20200405698 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF ANTIVIRAL AGENTS - Compositions and method of the present invention comprise novel formulations for increasing the effectiveness of antiviral agents and for preventing and treating symptoms associated with the common cold and viral infections. The present invention is directed to treating symptoms resulting from viral infections and diseases associated with Picornaviridae, Coronaviridae, Orthomyxoviridae, Paramyxovirinae, Reoviridae, and Adenoviridae. The novel formulations provided herein improve the therapeutic ratio of antiviral agents such as pleconaril. | 2020-12-31 |
20200405699 | TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND - Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1. | 2020-12-31 |
20200405700 | INHALABLE FORMULATION OF A SOLUTION CONTAINING FORMOTEROL FUMARATE AND ACLIDINIUM BROMIDE - The present invention discloses a liquid, propellant-free pharmaceutical formulation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical formulation comprising: (a) active substances selected from aclidinium bromide and formoterol fumarate; (b) a solvent; and (c) a pharmacologically acceptable preservative, optionally including a pharmacologically acceptable stabilizer, a pharmacologically acceptable solubilizing agent, or other pharmacologically acceptable additives. | 2020-12-31 |
20200405701 | PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANESULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-- 6-TRIFLUOROMETHYLPYRIDIN-3-YL)-ACRYLAMIDE AND METHOD FOR INHIBITING CRYSTAL FORMATION THEREOF - One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time. | 2020-12-31 |
20200405702 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS - The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases. | 2020-12-31 |
20200405703 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN INTEGRIN ALPHA4 ANTAGONIST FOR USE IN TREATING OCULAR INFLAMMATORY CONDITIONS - The invention relates to antagonists of integrin α4 and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for treating ocular inflammatory conditions, such as dry eye disease, non-infectious uveitis (e.g., anterior, intermediate, posterior, pan-uveitis), non-infectious conjunctivitis, iritis, or scleritis in animals, and particularly mammals, including humans. | 2020-12-31 |
20200405704 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. | 2020-12-31 |
20200405705 | Atropine Pharmaceutical Compositions - The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives. | 2020-12-31 |
20200405706 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS - The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor. | 2020-12-31 |
20200405707 | DIAZINYL AMINO ACRIDINES AND MEDICAL USES THEREOF - There is provided herein compounds of formula (I) and pharmaceutically-acceptable salts and/or detectably-labelled derivatives thereof, wherein R | 2020-12-31 |
20200405708 | TREATMENT OF HEREDITARY ANGIOEDEMA - Described herein are compositions comprising a highly selective at plasma kallikrein inhibitor and useful for the treatment of angioedema. | 2020-12-31 |
20200405709 | QUINOLINE DERIVATIVE FOR TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER - The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor. Specifically, the present invention relates to use of quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine in the treatment of triple-negative breast cancer, | 2020-12-31 |
20200405710 | COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS - The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (I) and/or (II) as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection: | 2020-12-31 |
20200405711 | OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USE - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 2020-12-31 |
20200405712 | METHOD OF TREATING BIPOLAR I AND II DISORDERS - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 2020-12-31 |
20200405713 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 2020-12-31 |
20200405714 | TADALAFIL FREE BASE-CONTAINING FILM DOSAGE FORM CONTAINING POLYETHYLENE GLYCOL-BASED POLYMER AND/OR VINYL PYRROLIDONE-BASED POLYMER AS DISPERSION STABILIZER - The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process. | 2020-12-31 |
20200405715 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND INFLAMMATORY DISEASES - The present disclosure is directed to, e.g., 3-substituted, 5-amine-substituted-cyclohex-2-en-1-one compounds, and method of treatment and making associated with the same compounds. | 2020-12-31 |
20200405716 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA - The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject. | 2020-12-31 |
20200405717 | TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS - Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor. | 2020-12-31 |
20200405718 | DOSING WITH AN AZOLOPYRIMIDINE COMPOUND - Provided herein are methods of treating a disease, disorder, or condition, mediated at least in part by the adenosine A | 2020-12-31 |
20200405719 | CANCER TREATMENT USING COMBINATION OF NEUTROPHIL MODULATOR WITH MODULATOR OF IMMUNE CHECKPOINT - The present disclosure provides methods of treating a cancer in a subject. The method includes a step of measuring a base level of a biomarker selected from a group consisting of hepatocyte growth factor, absolute neutrophil count, c-Met+ neutrophils and neutrophil to lymphocyte ratio (NLR) in the subject. The method also includes the steps of determining that the base level of said biomarker is equal or more than a threshold value or determining the change in the said biomarker upon administration of an immune checkpoint modulator is equal or more than a threshold value; and administering to the subject a combination of c-Met inhibitor and a modulator of an immune checkpoint. | 2020-12-31 |
20200405720 | CANCER DIAGNOSTIC AND TREATMENT - Bacterial species and the associated microbiome persist in tumors and metastases. Antibiotic treatment selectively reduces microbiome-induced tumor growth and can advantageously be included in treatment regimens. Accordingly, the present disclosure relates to, for example, the diagnosing cancer in a subject and providing identifying an effective treatment regimen for the subject. | 2020-12-31 |
20200405721 | G1T38 SUPERIOR DOSAGE REGIMES - A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25. | 2020-12-31 |
20200405722 | Methods for the Use of Low-Dose Immune Modulators Transiently for Treating Patients Undergoing Protein Replacement Therapy - The present disclosure provides compositions and methods for inducing immune tolerance in subjects suffering from metabolic diseases. | 2020-12-31 |
20200405723 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME - A compound, or a pharmaceutically acceptable salts or prodrugs thereof, having the chemical structure: | 2020-12-31 |
20200405724 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 - The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection. | 2020-12-31 |
20200405725 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF - A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases. | 2020-12-31 |
20200405726 | DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOF - This invention relates to deuterated analogs of etifoxine of Formula 1, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. Briefly, this invention is generally directed to deuterated analogs of etifoxine as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same. | 2020-12-31 |
20200405727 | NEW ALK INHIBITOR SENOLYTIC DRUGS - The present invention relates to the use of ALK tyrosine-kinase receptor inhibitors, in particular Alectinib, and compositions including it, as senolytic drug. In particular it relates to the use as senolytic drugs in a method of treatment of tumour or other pathological and incapacitating conditions associated to the cellular senescence. | 2020-12-31 |
20200405728 | METHODS OF PREVENTING AND TREATING HYPOGLYCEMIA IN TYPE 1 AND TYPE 2 DIABETES PATIENTS - Disclosed are methods for increasing glucagon secretion in response to exogenous insulin-induced hypoglycemia in patients with type 1 or type 2 diabetes. Also disclosed are methods of increasing glucagon secretion, and thus preventing or treating hypoglycemia, in patients with insulin producing tumors. The methods include administering a therapeutic amount of a histamine 1 receptor antagonist, a histamine 3 receptor antagonist, and/or a combination histamine 1/3 receptor antagonist. It may also be further advantageous to administer a therapeutic amount of a serotonin receptor antagonist in the methods disclosed herein. | 2020-12-31 |
20200405729 | METHOD OF TREATING HYPERTENSION - Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of desipramine or a salt thereof. The compositions include an effective amount of desipramine or a salt thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension. | 2020-12-31 |
20200405730 | PI3KGAMMA INHIBITORS - The present disclosure relates to PI3Kγ inhibitors and methods of their use. | 2020-12-31 |
20200405731 | METHOD AND COMPOSITION FOR ADMINISTERING PROSTAGLANDINS - A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is designed for inhalation for delivery of drugs to the pulmonary circulation in a rapid and therapeutically effective manner. | 2020-12-31 |
20200405732 | MONOLITHIC INTRAVAGINAL RINGS COMPRISING PROGESTERONE AND METHODS OF MAKING AND USES THEREOF - The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid. | 2020-12-31 |